AFib awareness: Stroke risks & advanced treatment options
Atrial fibrillation, or AFib, is a common heart rhythm disorder that is the leading cause of strokes. It creates an irregular heartbeat and increases the risk of blood clots forming in the heart. Those clots can break free, travel to the brain, and cause a stroke.
The risk of getting AFib increases with age, but anyone could develop it. Those with AFib are five times more likely to have a stroke and can experience various symptoms.
'Atrial fibrillation can be anywhere from being asymptomatic, meaning having no symptoms at all, to being in the hospital because you feel like you're having a heart attack. Some of these patients describe atrial fibrillation as, 'the big one', where they're sweaty, they're clammy, their chest hurts,' Ascension Bay Medical Center Cardiac Electrophysiologist Dr. Saeed Khaja said.
But there are some steps you can take to protect yourself. For example, smartwatches have sensors that monitor heart rate and can detect AFib. Early detection methods like this play a critical role in stroke prevention.
'The sooner you treat them, the more likely that you're going to keep it away and the less likely you're going to have a stroke,' Khaja said.
Talk to your doctor for other early detection options.
There's no cure for AFib, but there are advanced treatment options available, like pulsed field ablation.
'Pulse field, these electrical impulses that go to the heart that actually inactivate the part of the heart that causes AFib. And the best thing about it is that it does no damage to the tissue around,' Khaja said. 'Gone are the days when you just medicate and you wait till it gets bad. Now you can actually have a patient come to the lab. And I've had young people with their first or second incidence of atrial fibrillation coming to the lab and doing ablation, and now they're off of almost all medications and living a completely normal life, like it never happened.'
Ascension Sacred Heart Bay has performed the procedure on 381 patients.
For information on stroke warning signs or risk factors, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Temporary closure of Mason Street Bridge in Green Bay causes traffic delays
GREEN BAY, Wis. (WFRV) – The Mason Street Bridge, also known as the Tillman Bridge, was temporarily closed, including all on-ramps. Officials say the bridge was lifted for a passing vessel, but it failed to lock back into to Brown County Public Safety, the bridge has now reopened. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
7 hours ago
- Business Wire
Southern Glazer's Wine & Spirits Youth Alcohol Awareness Program Continues Efforts to Prevent Underage Drinking
MIAMI & DALLAS--(BUSINESS WIRE)--The Youth Alcohol Awareness and Education Foundation, Inc. – founded by Southern Glazer's Wine & Spirits (Southern Glazer's) to support the prevention of underage drinking – today announced that the Alcohol Education for High School online courses will return for the upcoming 2025-2026 school year. Students in Broward and Miami-Dade counties in Florida, Collin, Dallas, Denton, and Tarrant counties in Texas, and Bronx, Kings, Nassau, New York, Queens, and Richmond counties in New York will benefit from this form of alcohol education. The Youth Alcohol Awareness and Education Foundation, Inc. – founded by Southern Glazer's, to support the prevention of underage drinking – today announced that the Alcohol Education for High School online courses will return for the 2025-2026 school year. AlcoholEdu for High School, developed by EverFi, a company that delivers digital education on critical life skills, is a 90-minute interactive course designed for high school students. It includes science-based alcohol education, with engaging exercises that challenge perceptions, and encourage positive behaviors. The courses are based on five pillars: Knowing the Basics, Knowing Your Influences, Brain and Body, Smart Decisions, and Future Ready. Its goal is to equip students with the knowledge and awareness to make responsible choices about alcohol. The most recent 2024-2025 school year was a complete success as students' assessment scores in the AlcoholEdu for High School program in Florida, Texas and New York rose from 62% pre-lesson to 89% post-lesson, resulting in a 27 percent knowledge increase. Overall, 92% of students who took the course say that these educational sessions will help them make informed and thoughtful decisions for the future. Educators – who play an imperative role in this initiative – reported an extraordinary 94% positive rating across the board: they found value in the material taught in the classroom, noted that students found the materials compelling, and agreed that teacher-provided content was good or better. 'The content was self-contained; it was short enough for the students to stay interested but contained enough information to be educational,' said one of the educators. 'This course helps me get students information that I might not get time to cover in class.' The program launched in 2017 in South Florida. Southern Glazer's expanded support of the program to Texas in 2019 then New York in 2020. Since its start, the program has made a difference for 54,222 students, 331 high schools and has offered 79,660 hours of learning. School personnel and administration can reach out to the following individuals for more information on AlcoholEdu: About Southern Glazer's Wine & Spirits Southern Glazer's Wine & Spirits is the world's preeminent distributor of beverage alcohol, building brands for moments that matter. The multi-generational, family-owned Company has operations in 47 U.S. markets and Canada, as well as brokerage operations through its Southern Glazer's Travel Retail Sales & Export Division in the Caribbean, Central and South America. In 2025, Southern Glazer's was recognized by Newsweek as one of America's Greatest Workplaces for Diversity and America's Greatest Workplaces for Women, and was ranked by U.S. News & World Report as a Best Company to Work for Overall. Southern Glazer's urges all retail customers and adult consumers to market, sell, serve, and enjoy its products responsibly. For more information visit Follow us on Facebook, X and Instagram @sgwinespirits. About EVERFI EVERFI is an international technology company driving social impact through education to address key societal challenges like financial wellness, mental health, workplace conduct, and more. Founded in 2008, EVERFI has reached millions of K-12 and adult learners worldwide with its transformative digital educational content. Through a unique third-party payer model, EVERFI provides K-12 schools in the U.S. with access to essential educational resources at no cost, ensuring that students everywhere gain vital life skills. Recognized as one of the World's Most Innovative Companies by Fast Company and featured on Fortune Magazine's Impact 20 List and the GSC EdTech 150, EVERFI continues to shape the future of digital learning. To learn more about EVERFI, please visit or follow us on Facebook, Instagram, LinkedIn, or X/Twitter @EVERFI.
Business Wire
8 hours ago
- Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.
